Art. -Nr.: HY-N0853

Alisol A

5 Cited Publications

Kundenbewertung

Based on 5 publication(s) in Google Scholar

Alisol A is an orally active tetracyclic triterpenoid compound of the prototerpane type. Alisol A can be extracted from the rhizome of Alisma orientale. Alisol A activates AMPK/ACC/SREBP-1c, SIRT1, PPARα, inhibits MMP-2/-9, decreases inflammatory cytokine expression (IL-1β, IL-6, IL-8). Alisol A has anti-tumor activity against breast cancer and colorectal cancer. Alisol A has anti-obesity and anti-atherosclerotic activities. Alisol A can be used in the research of hepatitis B, breast cancer, colorectal cancer, atherosclerosis, and obesity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.59%
CAS. Nr.: 19885-10-0
Formel: C₃₀H₅₀O₅
Molecular Weight:490.72

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Alisol A Chemical Structure

CAS. Nr.: 19885-10-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (5)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target^[1]^[2]^[3]^[4]^[5]^[6]^[7]

MMP-9

MMP-2

PPARα

IL-6

IL-1β

IL-8

Alle AMPK Isoform-spezifische Produkte anzeigen :

Alle PPAR Isoform-spezifische Produkte anzeigen :

Alle MMP Isoform-spezifische Produkte anzeigen :

Alle Interleukin Related Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
Erythrocyte	IC₅₀	13.8 μM Compound: 57a	Antiplasmodial activity against Plasmodium falciparum K1 infected in human erythrocyte assessed as inhibition of parasite growth incubated for 72 hrs by [3H]-hypoxanthine incorporation based liquid scintillation counting method Antiplasmodial activity against Plasmodium falciparum K1 infected in human erythrocyte assessed as inhibition of parasite growth incubated for 72 hrs by [3H]-hypoxanthine incorporation based liquid scintillation counting method	[PMID: 35985254]
HepG2	EC₅₀	10.16 μM Compound: 23	Transactivation of FXR (unknown origin) transfected in HepG2 cells co-expressing pBSEP/pGL4.74 incubated for 24 hrs by luciferase reporter gene assay Transactivation of FXR (unknown origin) transfected in HepG2 cells co-expressing pBSEP/pGL4.74 incubated for 24 hrs by luciferase reporter gene assay	[PMID: 31494470]
HepG2 2.2.15	CC₅₀	0.062 mM Compound: 1	Cytotoxicity against human HepG2.2.15 cells Cytotoxicity against human HepG2.2.15 cells	[PMID: 18644720]
HepG2 2.2.15	IC₅₀	>2.4 mM Compound: 1	Antiviral activity against hepatitis B virus-infected human HepG2.2.15 cells assessed as inhibition of HBV e antigen secretion Antiviral activity against hepatitis B virus-infected human HepG2.2.15 cells assessed as inhibition of HBV e antigen secretion	[PMID: 18644720]
HepG2 2.2.15	IC₅₀	0.039 mM Compound: 1	Antiviral activity against hepatitis B virus-infected human HepG2.2.15 cells assessed as inhibition of HBV surface antigen secretion Antiviral activity against hepatitis B virus-infected human HepG2.2.15 cells assessed as inhibition of HBV surface antigen secretion	[PMID: 18644720]

In Vitro

Alisol A (2.5-40 μM; 24 h) suppresses proliferation, migration, and invasion in human breast cancer MDA-MB-231 cells^[3].
Alisol A (1-5 μM) concentration-dependently restores the levels of p-AMPK and p-ACC in HepG2 cells treated with free fatty acids (FFA)^[4].
Alisol A (40 μM; 24-72 h) inhibits the proliferation of human aortic endothelial cells (HAECs)^[5].
Alisol A (5-160 µM; 24 h) inhibits the proliferation of HCT-116 and HT-29 cells in a dose-dependent manner^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[3]

Cell Line:

MDA-MB-231
Concentration:

0, 5 μM
Incubation Time:

24 h
Result:

Downregulated MMP-2/-9.

In Vivo

Alisol A (100 mg/kg; i.p.; once daily; 4 weeks) significantly attenuates body weight and abdominal fat weight and activates the AMPK/ACC/SREBP-1c pathway in high-fat diet-induced obese mice^[4].
Alisol A (150 ppm; p.o.; in diet; 16 weeks) significantly reduces the aortic plaque area in ApoE^-/- mice with atherosclerosis, without obvious effect on blood lipid levels^[5].
Alisol A (25-100 mg/kg; i.g.; twice daily; 12 weeks) alleviates arterial plaque by activating AMPK/SIRT1 signaling pathway in apoE-deficient mice^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male C57BL/6 mice (6 weeks old) with high-fat diet-induced obesity^[4]
Dosage:

100 mg/kg
Administration:

Intraperitoneal injection, once daily, for 4 weeks
Result:

Reduced body weight and abdominal fat mass, improved plasma lipid profiles (decreased TC, TG, LDL-C, NEFA, FABP4).
Enhanced glucose tolerance and insulin sensitivity, alleviated hepatic steatosis (reduced fat vacuoles and lipid deposition).
Decreased inflammatory cytokine expression (TNF-α, IL-1β, IL-6, IL-8) in adipose tissue, and activated the AMPK/ACC/SREBP-1c pathway (increased p-AMPK, p-ACC, decreased SREBP-1c) in liver, skeletal muscle, and adipose tissue.

Animal Model:

Male C57BL/6 background ApoE^-/- mice (6-week-old), high-fat diet-induced atherosclerosis model^[7]
Dosage:

25 mg/kg, 100 mg/kg
Administration:

Intragastric administration, twice daily, 12 weeks
Result:

Attenuated high-fat diet-induced body weight gain, reduced aortic plaque area, widened the inner diameter of the aortic arch.
Inhibited the expression of ICAM-1, IL-6, and MMP-9 in aortic plaques, and increased the expression of PPARα, PPARδ, p-AMPK, SIRT1, and IkBa in the liver.

Chemical Information

CAS. Nr. 19885-10-0
Appearance Solid
Molecular Weight 490.72
Formel C₃₀H₅₀O₅
Color White to light yellow
SMILES

C[C@]([C@@]1(C2=C([C@H](C)C[C@H](O)[C@@H](O)C(C)(O)C)CC1)C)(CC[C@@]3([H])C4(C)C)[C@]([C@H](C2)O)([H])[C@]3(CCC4=O)C
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (5)

All

Sort by:

Journal Impact Factor

Molecules

Alisol A Suppresses Proliferation, Migration, and Invasion in Human Breast Cancer MDA-MB-231 Cells. [Abstract]

2019 Oct 10;24(20):3651. PMID: 31658635
Vet Microbiol

Identification and evaluation of Nordihydroguaiaretic acid (NDGA) as an active traditional Chinese medicine compound inhibiting the 3C-like protease of feline infectious peritonitis virus. [Abstract]

2025 Sep 15:310:110730. PMID: 40976146
Nephrology (Carlton)

Alisol A inhibits the circ_0001831/miR-346/LIN28B pathway to ameliorate high glucose-induced injury of human renal mesangial cells. [Abstract]

2024 Mar;29(3):154-163. PMID: 38013222
Biomed Pharmacother

A novel Alisma orientale extract alleviates non-alcoholic steatohepatitis in mice via modulation of PPARα signaling pathway. [Abstract]

2024 Jun 7:176:116908. PMID: 38850668
Research Square Preprint

2021 Feb.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (203.78 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.0378 mL

10.1891 mL

20.3782 mL

5 mM

0.4076 mL

2.0378 mL

4.0756 mL

10 mM

0.2038 mL

1.0189 mL

2.0378 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (5.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.09 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Matsuda H, et al. Studies on Alismatis Rhizoma. II. Anti-complementary activities of methanol extract and terpene components from Alismatis Rhizoma (dried rhizome of Alisma orientale). Biol Pharm Bull. 1998 Dec;21(12):1317-21. [Content Brief]

[2]. Zhang Q, et al. Anti-HBV agents. Part 1: Synthesis of alisol A derivatives: a new class of hepatitis B virus inhibitors. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4647-50. [Content Brief]

[3]. Lou C, et al. Alisol A Suppresses Proliferation, Migration, and Invasion in Human Breast Cancer MDA-MB-231 Cells. Molecules. 2019 Oct 10;24(20):3651. [Content Brief]

[4]. Ho C, et al. Alisol A attenuates high-fat-diet-induced obesity and metabolic disorders via the AMPK/ACC/SREBP-1c pathway. J Cell Mol Med. 2019 Aug;23(8):5108-5118. [Content Brief]

[5]. Ma Y, et al. Alisol A inhibits and stabilizes atherosclerotic plaques by protecting vascular endothelial cells. Front Pharmacol. 2024 Oct 25;15:1493948. [Content Brief]

[6]. Han W, et al. Alisol A attenuates malignant phenotypes of colorectal cancer cells by inactivating PI3K/Akt signaling. Oncol Lett. 2022 Jun 7;24(2):249. [Content Brief]

[7]. Wang K, et al. Alisol A Alleviates Arterial Plaque by Activating AMPK/SIRT1 Signaling Pathway in apoE-Deficient Mice. Front Pharmacol. 2020 Nov 2;11:580073. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.0378 mL	10.1891 mL	20.3782 mL	50.9455 mL
	5 mM	0.4076 mL	2.0378 mL	4.0756 mL	10.1891 mL
	10 mM	0.2038 mL	1.0189 mL	2.0378 mL	5.0946 mL
	15 mM	0.1359 mL	0.6793 mL	1.3585 mL	3.3964 mL
	20 mM	0.1019 mL	0.5095 mL	1.0189 mL	2.5473 mL
	25 mM	0.0815 mL	0.4076 mL	0.8151 mL	2.0378 mL
	30 mM	0.0679 mL	0.3396 mL	0.6793 mL	1.6982 mL
	40 mM	0.0509 mL	0.2547 mL	0.5095 mL	1.2736 mL
	50 mM	0.0408 mL	0.2038 mL	0.4076 mL	1.0189 mL
	60 mM	0.0340 mL	0.1698 mL	0.3396 mL	0.8491 mL
	80 mM	0.0255 mL	0.1274 mL	0.2547 mL	0.6368 mL
	100 mM	0.0204 mL	0.1019 mL	0.2038 mL	0.5095 mL

Keywords

Alisol A

5 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Alisol A

Cell Cycle/DNA Damage Compound Library

Epigenetics Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

PI3K/Akt/mTOR Compound Library

Natural Product Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Glycolysis Compound Library

Pyroptosis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Lipid Metabolism Compound Library

Glucose Metabolism Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Nuclear Receptor Compound Library

Chemokine Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Metabolic Enzyme Compound Library

Protease Inhibitor Library

Cysteine Targeted Covalent Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

RO5 Drug-like Natural Product Library

Lactic Acid Metabolic Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Natural Product Diversity Scaffold Library

Publications Citing Use of MedChemExpress (MCE) Alisol A

Alle AMPK Isoform-spezifische Produkte anzeigen

Alle PPAR Isoform-spezifische Produkte anzeigen

Alle MMP Isoform-spezifische Produkte anzeigen

Alle Interleukin Related Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (5)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Alisol A Related Classifications

HY-N0853 Related Classifications